By Paula Z. Segal
Gladys Mensing had diabetic gastroparesis, a chronic condition caused by nerve damage. For a person suffering from this illness, the stomach takes too long to empty its contents. Symptoms include heartburn, nausea, vomiting undigested food, and weight loss. In 2001, Mensing’s doctor prescribed Reglan to treat her symptoms, and her pharmacist filled the prescription with a generic version of the drug. Ms. Mensing took the generic for four years, and in the process developed tardive dyskinesia, a severe neurological movement disorder characterized by involuntary movements, especially of the lower face. Tardive means "delayed" and dyskinesia means "abnormal movement” -- symptoms include facial grimacing, jaw swinging, repetitive chewing, and tongue thrusting. While Ms. Mensing stopped taking the drug in 2005, the disorder is often irreversible and there are no known treatments.
Ms. Mensing sued the manufacturers of the drug she took (Pliva, Inc., Teva Pharmaceuticals USA, Inc., UDL Laboratories, Inc. and Actavis Elizabeth, LLC.) for failing to warn her and other consumers of the side effects of their drug and misrepresenting its safety. Doctors and consumers use the labels on prescription drugs to decide what drugs are safe enough to take and prescribe. Neither the label on Reglan or the label of the generic Ms. Mensing took warned of the actual quantity of risk of this severe disorder when taking the drug over a long period of time. The label said that the risk of any neurological disorder from taking the drug for at least three months was 1 in 500. It did not warn that certain groups of patients are more likely to develop the condition. The Food and Drug Administration (FDA) says that the risk for tardive dyskinesia alone is 20% - one in five patients can develop the debilitating condition after taking the drug for just three months. The FDA has also found that the elderly, especially elderly women like Ms. Mensing, are more likely to develop the condition. Yet Reglan had not updated its labels since 1985, just five years after Reglan was first approved by the FDA. Had Ms. Mensing and her doctor known about these risks, they would not have decided on long-term treatment with Reglan or its generic version.
Ms. Mensing sued the drug manufacturers in federal court. The generic manufacturer had a clever answer: It claimed that it could not put anything on its label that the name brand did not have on its label. So when Reglan left out its long term side effects, the generic manufacturer claimed that the law said they had to leave them out too -- even if Reglan was mistaken or lying to its customers. The generic manufacturer argued that federal law forbid them from taking steps to warn their consumers of hazards they knew about if the name brand manufacturer didn’t warn against those hazards. The Minnesota federal district court agreed with the drug company and dismissed Ms. Mensing’s lawsuit. She refused to give up and appealed to the Eighth Circuit Court.
In the end, Ms. Mensing’s perseverance paid off. A week after she filed her appeal, on February 26, 2009, the Food and Drug Administration (FDA) ordered Reglan to update its labels to reflect the known risks. In April 2009, the United States Department of Justice, who had filed a ‘friend of the court’ brief on behalf of the drug companies during the first trial, withdrew its support for the drug companies. On November 27, 2009, the Eighth Circuit Court of Appeals held the generic drug manufacturers accountable for labeling the drugs they manufacture. This is extremely important for drug safety. Over 70% of prescriptions for drugs in the US are filled by generic versions of name brand drugs. The court has refused to give the manufacturers of generic drugs a pass when it comes to labeling.
District courts in Vermont and Illinois have made similar rulings. The courts are holding generic drug manufacturers accountable for the side effects of the drugs that they manufacture, no matter what the name brands put on their labels. Such instances continue to remind us that the courts are indeed powerful tools, primarily intended to protect the American public, not American commerce.
Paula Z. Segal is a second year student at City University of New York
School of Law and a Haywood Burns Fellow in Civil and Human Rights.
Before law school, she taught English to Speakers of Other Languages
and continues to develop materials for ESOL instructors to connect
language and life skills. She is also working with the New York Civil
Liberties Union to reduce the school to prison pipeline and coordinates
the CUNY Street Law Team, which brings the law to New York City high
school students and community groups. For more on the school to prison
pipeline, go to http://www.nyclu.org/issues/
(Photo by Pink Sherbet Photography.)